This site is intended only for healthcare professionals resident in India

Search

Menu

Close

Sign InLog Out
Our medicinesTherapy areasExplore ContentExplore contentMaterialsVideosLet's connectLet's ConnectPfizer medical information

Menu

Close

AboutIntroducing Enbrel®Heritage of Enbrel®IndicationsTherapeutic IndicationsRheumatoid ArthritisJuvenile Idiopathic ArthritisPsoriatic ArthritisAxial SpondyloarthritisPsoriasis & Paediatric PsoriasisMechanism of actionMode of ActionHalf-lifeDosingDosingRheumatoid Arthritis, Psoriatic Arthritis & Axial SpondyloarthritisJuvenile Idiopathic ArthritisPsoriasisPaediatric PsoriasisAdministration & StorageAdministrationMYCLIC®StorageEfficacy & SafetyEfficacyRapid EffectivenessSustained EffectivenessEffectiveness With Monotherapy or Combination TherapySafetyTolerability Across IndicationsSummary of Prescribing InformationImmunogenicityImmunogenicity & Clinical ResponseImmunogenicity & Enbrel®Experience & InsightsExperience & InsightManufacturingPatient StoriesRheumatoid ArthritisPatient With an Increased Risk of Serious InfectionsMTX-IR PatientPatient Who Is Considering Starting a FamilyElderly-onset RA PatientYoung Patient Worried About the Lifelong Impact of RAYoung Patient Worried About Treatments That Lose Effectiveness Over TimeJuvenile Idiopathic ArthritisJuvenile PatientPatient Moving From Childhood to AdolescenceAxial SpondyloarthritisAS Patients With Heel EnthesitisAS Patients With Functional LimitationsAdvanced AS PatientsPsoriatic Arthritis & PsoriasisPsO Patient With Severe SymptomsPsO Patients With Cyclical SymptomsPsA Patient With Metabolic SyndromePsA Patient With Multiple Skin & Joint SymptomsSupport & ServicesSupport & ServicesUsing Enbrel®Summary of Prescribing InformationPatient ResourcesEventsMaterialsVideos

PsO Patients With Cyclical Symptoms

Meet Divyam, a 26-year-old with moderate plaque PsO.1

  

‘My job takes me all over the country and it is important that I make a good first impression. A psoriasis flare is the last thing I need as people think I have got an infectious disease’.2

The lesions come and go,3,4 and if I knew when they would appear, it would make my life easier. I have been prescribed PUVA and ciclosporin, but they are not always effective. So, I generally cover up when I meet new people’.

The course and progress of PsO is unpredictable3,4

Note: This is a hypothetical case for representation purpose only.

Patients with PsO such as Divyam whose symptoms have cyclical benefit from individualised treatment with Enbrel®5-9

  • Improvements observed over 54 weeks with both continuous and intermittent treatment across a wide range of physician- and patient-reported measures5-7,*
     
    • Patients who paused and resumed treatment recaptured response and experienced sustained benefit5-8
  • Patients with PsO continue to benefit from long-term individualised Enbrel®9,†
     
    • Improvements maintained up to 72 weeks with both continuous and interrupted treatment9
       
    • Both continuous and interrupted treatments were generally well-tolerated through 2.5 years9
   
Enbrel® is the only biologic approved for continuous or intermittent dosing in plaque PsO.10

   

From CRYSTEL, a randomised, open-label study that compared continuous and intermittent Enbrel® dosing regimens in 720 patients with PsO.5,*

  

PASI Improvement Over 54 Weeks5

  

  

P<0.01 for both groups versus baseline from Week 3 onwards. 
Adapted from Ortonne JP, et al. 2008.

  

Please consult the LPD for contraindications, warnings, precautions and other important safety information.

  

Please note: The examples described here are not of actual patients, but fictitious representations of scenarios for which Enbrel® (etanercept) could be considered.

  

*From CRYSTEL, a randomised, open-label, multicentre study of 720 patients with PsO treated (1:1) with continuous or intermittent Enbrel®.5 From Weeks 3 to 54, both dose regimens significantly improved PGA and PASI scores versus baseline.5,8 Significant improvements were also observed across a range of PROs, including DLQI, EQ-5D, HADS-D, HADS-A and SF-36 Vitality.6

  

Study design: Ortonne JP, et al. 2008.

  

In CRYSTEL, the continuous therapy group received Enbrel® 25 mg BIW throughout the 54-week study. The intermittent therapy group received Enbrel® 50 mg BIW for up to 12 weeks. Therapy was temporarily paused during that time when a target response (PGA ≤2) was achieved. When a patient subsequently relapsed (PGA ≥3), Enbrel® (25 mg BIW for up to 24 weeks) was re-initiated until the target response was regained. Patients who failed to achieve the initial target response by Week 12, but whose PGA score improved by at least 1 unit, continued treatment with Enbrel® 25 mg BIW for up to 24 weeks or until the target response was reached. In both treatment groups, patients who did not show improvement of at least 1 unit from baseline PGA by Week 12 were considered treatment failures, and were discontinued from the study.5
The trial’s primary endpoint was mean PGA over 54 weeks. Secondary endpoints included changes from baseline in mean PGA and PASI, and patient satisfaction with current PsO treatment.5
PROs evaluated included DLQI, EQ-5D, HADS and the SF-36 Vitality subscale.6

  

From a 72-week, long-term extension study. In total, 912 patients with PsO received 50 mg Enbrel® QW for 12 weeks; thereafter, patients could maintain 50 mg QW (n=321) or escalate to 50 mg BIW (n=591) based on 1 of 3 predetermined criteria. Patients had experienced an interruption in Enbrel® treatment between the last dose of the parent Phase 3 study and the first dose of this extension study, and comparisons were made between those with treatment gaps of ≤30 versus >30 days.9

  

BIW, twice a week; DLQI, Dermatology Life Quality Index; CRYSTEL, Clinical Randomized Year-long Study assessing the safety and efficacy of EnbreL in psoriasis; EQ-5D, EuroQoL-5D; HADS-A, Hospital Anxiety and Depression Scale-Anxiety; HADS-D, Hospital Anxiety and Depression Scale-Depression; PASI, Psoriasis Area and Severity Index; PGA, physician global assessment; PRO, patient-reported outcome; PsO, psoriasis; PUVA, psoralen plus ultraviolet A radiation; QW, once a week; SF-36, Short Form-36; SmPC, summary of product characteristics.

  

References:

Enbrel. Local product document. Version LPDENB062021.Łakuta P, Marcinkiewicz K, Bergler-Czop B, Brzezińska-Wcisło L. How does stigma affect people with psoriasis? Postepy Dermatol Alergol. 2017;34(1):36-41.Mitra AD, Mitra A. Clinical presentation of psoriasis. In: Lima H, ed. Psoriasis-Types, Causes and Medication. IntechOpen;2013:39-53.Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis. 2005;64(Suppl 2):ii18-ii25.Ortonne JP, Griffiths CEM, Daudén E, et al. Efficacy and safety of continuous versus paused etanercept treatment in patients with moderate-to-severe psoriasis over 54 weeks: the CRYSTEL study. Expert Rev Dermatol. 2008;3(6):657-665.Daudén E, Griffiths CE, Ortonne JP, et al. Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study. J Eur Acad Dermatol Venereol. 2009;23(12):1374-1382. 2010;101(Suppl 1):18-25.Herrera E, Alcaide AJ. Uso intermitente de etanercept en psoriasis [Intermittent use of etanercept in psoriasis]. Actas Dermosifiliogr. 2010;101 Suppl 1:18-25.Ortonne JP, Taïeb A, Ormerod AD, et al. Patients with moderate-to-severe psoriasis recapture clinical response during re-treatment with etanercept. Br J Dermatol. 2009;161(5):1190-1195.Leonardi C, Strober B, Gottlieb AB, et al. Long-term safety and efficacy of etanercept in patients with psoriasis: an open-label study. J Drugs Dermatol. 2010;9(8):928-937.Enbrel license extended to continuous treatment of psoriasis. PharmaTimes online. July 2009. Accessed June 2022. http://www.pharmatimes.com/news/enbrel_license_extended_to_continuous_treatment_of_psoriasis_983939

  

Please click the Prescribing Information link to view the safety and adverse events information of Enbrel®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.

    

PP-ENB-IND-0814 August 2022

    

Psoriatic Arthritis & Psoriasis
PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign in or RegisterSign inRegisterAccountSign Out
 
These pages are not intended for patients or for members of the general public. The web pages contain promotional content. For the use only of Registered Medical Practitioners or a Hospital or a Laboratory. Full prescribing information available on request. For more details on, Who is a Registered Medical Practitioner, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April2021.
​​​​​​​
Address: The Capital,  A Wing, 1802, 18th Floor, Plot No. C-70, ‘G’ Block, Bandra Kurla Complex, Bandra East, Mumbai – 400051, India.
 
PP-ENB-IND-0814

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

ButtonButton

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.

Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.

Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.

 
Copyright © 2022 Pfizer Limited, India. All rights reserved. Applicable for Pfizer Products, Product Microsites and Therapy Areas section of the website:
  • All content published herein is intended and strictly only for informational, educational, academic and/or research purposes and shall not be utilized to diagnose or treat a health problem or disease without referring to the full prescribing information for list of approved indications as contained in the product package insert
  • ​​​​​​​While due care and caution has been taken to ensure that the content herein is free from mistakes or omissions, Pfizer makes no claims, promises or guarantees about the accuracy, completeness or adequacy of the information herein
 
For the use of Registered Medical Practitioners only*

These pages are not intended for patients or for members of the general public. The web pages contain promotional content.


If you select 'No', you will be redirected to Pfizer.co.in

For more details on, Who is a Registered Medical Practitioner*, please visit https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
​​​​​​​Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.


PP-UNP-IND-0012 July 2022
Yes No
You are now leaving PfizerPro website
​​​​​​​ ​
​​​​​You are now leaving Pfizer Pro website and will be redirected to another website. Note that you will be governed by the Terms & Conditions and Privacy Policy of the external website. Would you like to continue?

PP-UNP-IND-0012 July 2022


​​​​​​​